key: cord-0846956-83aa34vi authors: Nasir, Zil H.; Mertz, Dominik; Nieuwlaat, Robby; Santesso, Nancy; Lotfi, Tamara; Motilall, Ashley; Moja, Lorenzo; Mbuagbaw, Lawrence; Klugar, Miloslav; Turgeon, Alexis F.; Mathew, Joseph L.; Canelo-Aybar, Carlos; Pottie, Kevin; Dewidar, Omar; Langendam, Miranda W.; Iorio, Alfonso; Vist, Gunn Elisabeth; Meerpohl, Joerg J.; Flottorp, Signe; Kredo, Tamara; Piggott, Thomas; Mathews, Micayla; Qaseem, Amir; Chu, Derek K.; Tugwell, Peter; Klugarová, Jitka; Nelson, Harrison; Hussein, Heba; Suvada, Jozef; Neumann, Ignacio; Schünemann, Holger J. title: An evaluation of the eCOVID19 Recommendation Map identified diverging Clinical and Public Health guidance date: 2022-03-24 journal: J Clin Epidemiol DOI: 10.1016/j.jclinepi.2022.03.008 sha: 15d3b3617a298bfde1674e33580e203118ad5fe2 doc_id: 846956 cord_uid: 83aa34vi Objective To describe divergence between actionable statements issued by COVID-19 guideline developers catalogued on the “COVID-19 Recommendations and Gateway to Contextualization” platform. Study Design and Setting We defined divergence as at least two comparable actionable statements with different explicit judgements of strength, direction or subgroup consideration of the population or intervention. We applied content analysis to compare guideline development methods for a sample of diverging statements and to evaluate factors associated with divergence. Results Of the 138 guidelines evaluated, 85 (62%) contained at least one statement that diverged from another guideline. We identified 223 diverging statements in these 85 guidelines. We grouped statements into 66 clusters. Each cluster addressed the same population, intervention, and comparator group or just similar interventions. Clinical practice statements were more likely to diverge in explicit judgment of strength or direction compared to public health statements (Cramer’s V = 0.7, Fisher’s exact test; P <0.001). Statements were more likely to diverge in strength than direction. Date of publication, utilized evidence, interpretation of evidence, and contextualization considerations were associated with divergence. Conclusion More than half of the assessed guidelines issued at least one diverging statement. This study helps understanding the types of differences between guidelines issuing comparable statements and factors associated with their divergence. We have developed a digital platform (COVID-19.recmap.org) classifying and presenting actionable statements published in guidance documents for the management of COVID-19. 1 Alongside each actionable statement issued on this recommendation map (RecMap), we extracted explicit judgements of strength and direction and considerations such as Evidence-to-Decision (EtDs) frameworks when issued by guideline authors to catalogue advice about COVID- 19 . We noted important discrepancies of the content of the RecMap that may confuse users. Discrepancies can exist between how those synthesizing and presenting research evidence interpret it. This can lead to confusion amongst evidence users. Studies have specifically evaluated discordance in the results and conclusions of systematic reviews answering equivalent research questions. 2, 3 To select between discording reviews, Jadad and colleagues created a decision tool for stakeholders to apply when making clinical or policy decisions which incorporated a comparison of the search strategy and metanalytical processes used for each review. 2 Moja and colleagues utilized this decision tool to examine how frequent duplicate systematic reviews give different results and factors contributing to their discordance. 3 The term discordance has similarly been used in guideline development work to describe differences between the strength of recommendations and their certainty of evidence. 4 Although there is generally agreement among guideline developers, a different concept relates to scenarios when developers create recommendations or other actionable statements 5 that do not align with those from other guideline developers. We define this as divergence of actionable statements. This divergence can lead to confusion among users of recommendations if divergence is unexplained. The primary objective of this study was to J o u r n a l P r e -p r o o f explore the explicit judgements or subgroup considerations of comparable actionable statements on the RecMap that are associated with divergence. Our secondary objective was to investigate factors associated with this divergence. There are two classifications of divergence in our study. The first classification is any explicit difference in judgements that influence the strength or direction of two or more actionable statements (Divergence based on guideline developer judgement). When grouping this type of divergence, we used the PICO model to formulate a condition where statements in different guidelines addressed the same population (P) to judge whether a specific intervention (I) or comparator (C) intervention should be implemented. The second classification is any difference within subgroups of the recommendation's target population or in specific elements, e.g., variation in frequencies, dosages, units, or time intervals, of an otherwise similar intervention (Divergence based on subgroup considerations). Examples of the classifications and subclassifications of divergence can be found in Table 1. J o u r n a l P r e -p r o o f The use of facemasks in children in public settings Not recommended for children younger than two years Masks should not be put on children younger than two years (April 2021) Not recommended for children younger than five years World Health Organization: Children aged five years and under should not be required to wear masks (Dec. 2020) Intervention subgroup (different units) Recommended one metre distance Teachers and support staff should keep at least one metre apart from each other and from students (Sep. 2020) Recommended two metres distance Office of the Deputy Prime Minister -Ministry for Health: Keep two metres between staff and students (Aug. 2020) Figure 1 describes the step-by-step approach we followed. The inclusion criteria for identifying guidance documents to extract relevant recommendations for the RecMap are described in Appendix A. 1 Actionable statements can be divided based on their methodological rigour as formal or informal recommendations (Appendix A). 5 We reviewed both types of statements displayed on the RecMap (COVID19.recmap.org). Our approach to evaluating J o u r n a l P r e -p r o o f We flagged and subsequently aggregated all diverging statements with the same PICO elements but with different explicit judgements of strength or direction as one type of clusters (Appendix A). We also aggregated actionable statements for the same intervention but with different subgroup considerations as separate clusters. For statements with explicit judgements, we coded recommendations on a 4-point ordinal scale using the strength of recommendations as described in the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach (Appendix A). 5, 6 When possible, we transformed other grades of recommendations to GRADE in GRADEpro (www.gradepro.org) using a framework applied for the RecMap. 7 We performed descriptive statistics to assess the frequency of guidelines containing one or more diverging statements from at least one other guideline in our sample. We evaluated the mean and range of diverging statements in our clusters. We conducted a Fisher's exact test to evaluate if there was an observed difference in the type of divergence (i.e., explicit judgement or subgroup consideration) between clinical and public health statements. We used content analysis to compare differences in guideline development methods between actionable statements grouped in the same cluster. We randomly selected six clusters and purposefully selected an additional six clusters from the World Health Organization (WHO) to achieve information saturation. We developed a J o u r n a l P r e -p r o o f categorization matrix consisting of four major themes using a deductive approach (Appendix C) where each theme represented methodological steps in the guideline development process that could be compared between diverging statements. We used Jadad's decision tool 2 and reviewed standardized approaches of guideline development to form themes. 8-10 A single reviewer (ZN) evaluated each guideline in our sample of clusters and recorded information that corresponded with each theme in the matrix. A second reviewer (AM) revised, flagged, and inputted any missing information under each theme for completeness and so all details were available for reproducibility. Any differences between reviewers were noted and resolved through consensus. We identified 138 guidelines that allowed us to explore the phenomenon of divergence and explore factors associated with it. Eighty-five (62%) of these guidelines issued at least one diverging statement from another guideline for the same PICO or intervention. We found a total 223 diverging statements in these 85 guidelines that allowed us to evaluate and describe the phenomenon of divergence (out of at least 1330 actionable statements that were available on the RecMap at the time of our evaluation). Ninety-nine (44%) diverging statements were related to clinical interventions and 124 (56%) to public health interventions, respectively. Twenty-four (11%) of these statements used gradings that were readjusted to match GRADE. 7 We observed 115 (52%) statements diverging in explicit judgment of strength or direction and 108 (48%) statements diverging in subgroup considerations of the population or intervention. We aggregated the 223 statements to 66 clusters. Each cluster represented diverging statements with the same PICO or overarching intervention as described above (Appendix A). Twenty-nine (44%) of the clusters contained clinical interventions and 37 (56%) contained public health interventions ( Table 2 ). The mean number of diverging actionable statements in our clusters was 3.4 (SD: 1.5) and the number of statements per cluster ranged from a minimum of two to a maximum of eight. J o u r n a l P r e -p r o o f Thirty-four clusters diverged in explicit judgment of strength or direction and 32 clusters diverged in subgroup considerations of the population or intervention ( J o u r n a l P r e -p r o o f Twenty-one guidelines with diverging statements were included in our 12 clusters evaluated for content analysis. We have organized the methodological differences into four major categories (Table 4 ). J o u r n a l P r e -p r o o f Other guidelines with diverging statements applied different bodies of evidence for reasons other than most recent literature review. One cluster issued diverging statements for delaying the second dose of COVID-19 vaccines that require two complete doses. 14-16 CDC in March, 2021 recognized the limited direct evidence concerning the efficacy and effectiveness of extending the interval beyond 6-weeks to recommend against any further delay. 14 15 Consequently, the National Advisory Committee on Immunization deliberated on whether it was feasible to extend the second dose, so more members of their population are vaccinated. They applied evidence from studies evaluating vaccine effectiveness after one dose and population modelling studies. 15 None of their included studies directly assessed delaying the second dose for a period of 4-months because of insufficient evidence. Difference in the interpretation and certainty of evidence were evident for remdesivir: WHO issued a conditional recommendation against its use whereas other guidelines issued conditional recommendations favouring its use in patients with moderate to severe COVID-19. [17] [18] [19] [20] [21] [22] [23] [24] Most guidelines utilized evidence from the same randomized clinical trials including the ACTT-1 [17] [18] [19] [20] [21] [22] [23] [24] and WHO Solidarity studies. [17] [18] [19] [20] [21] [22] [23] While WHO 17 graded the overall certainty of applied evidence as low, guidelines issued by the National COVID-19 Clinical Taskforce of Australia, 18 Infectious Disease Society of America (IDSA), 19 and National Institute of Health Care Excellence (NICE) 20 graded the certainty of evidence as moderate. When comparing the balance of effects, WHO concluded there was insufficient evidence to currently prove remdesivir has an effect for patient-important outcomes such as mortality, need for mechanical ventilation, and time to clinical improvement. They balanced this with the high costs, resource requirements, and barriers in low and middle-income countries to recommend against its use. 17 Conversely, the Australian Taskforce concluded that remdesivir has small net benefits or little differences compared to alternative options. This judgement was based on remdesivir's safety profile, probable reduction of death, and probable reduction of serious adverse events. 18 When comparing study outcomes, the Solidarity trial reported no J o u r n a l P r e -p r o o f differences in outcomes of mortality and length of hospital stay. 20 However, the ACTT-1 trial reported improved time to recovery and less percentage of patients progressing to invasive ventilation. 20 Consequently, different interpretation of these studies may be associated with different judgements. We observed explicit or implicit differences in contextualization considerations We evaluated the frequency of guidelines containing diverging actionable statements for the management COVID-19 by applying an iterative search, screening and review process using the COVID-19 Recommendations and Gateway to Contextualization RecMap. At the time of evaluation, 62% of the included guidelines contained at least one diverging statement from at least one other guideline. Within these guidelines, we identified 223 total diverging statements. Out content analysis showed differences in methodological factors including date of publication or most recent literature search, utilized evidence, interpretation of evidence and their assessments of quality between guidelines containing comparable diverging statements. We also observed differences in contextualization criteria including judgements of cost-effectiveness and patient values between guidelines. We have developed a meaningful technique for those who need to understand differences between guideline recommendations to categorize the reasons for differences. The results from our study can also be used to clarify misperceptions among decision-makers by promoting transparency in guideline development processes. Strengths in our study include the application of a rigorous search strategy to organize actionable statements from guidelines on the RecMap and using two independent reviewers for verification of divergence and content analysis. Nonetheless, we could not quantify the exact number of actionable statements assessed from guidelines not uploaded to the RecMap, but the results suggest that divergence is common and not always explained. Given the large to utilize our content-analysis themes or adopt existing methods 2,3 by appraising differences in the date of literature review, applied evidence, interpretation of evidence, and context-specific considerations between diverging statements to decide which statements are supported by the best available evidence and will be most appropriate to implement in their setting. This idea is the core principle behind the GRADE 'adolopment' approach, a process that entails evaluating circumstantial EtD criteria from existing recommendations to decide whether they are appropriate to adopt or adapt in a new context or create new recommendations for better contextualization. 27 Guideline developers can therefore review regional evidence to revaluate judgements of EtD criteria or ultimately change the strength or direction of existing recommendations to reflect the new setting it will be applied. For example, when guideline developers from a low-income region are deciding to adopt or adapt an intervention that is recommended for implementation in a high-income region, they may choose to implement a more cost-effective alternative with similar clinical outcomes instead of the original intervention. This new recommendation will therefore diverge in direction from the original statement but may yield better outcomes in the new setting. Agreement between guidelines is important in other circumstances. For example, two diverging statements may differ in the direction of the recommendation, and one guideline may issue a strong recommendation. Depending on which alternative option is implemented, inequities could increase between settings if one intervention results in better outcomes than the other. Furthermore, the guideline development process aims to use evidence-informed methods to develop trustworthy statements. Divergence can ultimately affect the quality of these statements, especially when they are associated with the use of outdated evidence, incomplete evidence, or even differences in the interpretation of similar evidence when explanations for these different interpretations are not clarified by guideline authors. In these situations, it would be difficult to justify divergence. This may reduce public trust in the scientific community, which may lead to greater hesitancy to comply with health regulations. Furthermore, future studies should evaluate if these associations of divergence are linked with causation. If divergence is observed and caused by methodological differences, guideline developers will need to refine their procedures for developing actionable statements. This includes adopting methods, such as living guideline processes 29 , to guarantee timely updates of actionable statements to ensure they are supported by the best available evidence. We utilized a comprehensive international database to identify and describe differences between comparable statements for COVID-19, a phenomenon that we call divergence. We subsequently examined legitimate and justified methodological differences associated with divergence that can be used to assess causation in future studies. This research was funded by CIHR grant numbers FRN VR4-172741 & GA3-177732 and support for extracting information for the RecMap was also provided by the World Health Organization, but not specifically for the goals of this study. The sponsors had no role in the design or interpretation of the data. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the interpretations, decisions, or policies of any national or international institution involved in the analyses, including the World Health Organization. The authors declare no conflicts of interest. We would like to thank the following RecMap collaborators for their contribution to the Additionally, the RecMap captures and presents actionable statements from other selfreported guidelines and guideline societies that provide recommendations for COVID-19 by conducting biweekly searches in a list of databases found here. 1 These documents need to meet the criteria of a guideline, which is assessed by two members on the RecMap team. 1 J o u r n a l P r e -p r o o f Actionable statements on the RecMap and in our study can be classified as formal recommendations and informal recommendations (Table A1 ). More details about the different classifications and subclassifications of actionable statements can be found here. 2 In general, and for the purpose of this study, formal recommendations are formulated by applying a rigorous guideline development process which entails a literature review to summarize the evidence relevant to the recommendation, an assessment of the quality of that evidence, and an explicit judgement of the recommendations' strength and direction (Table A2 ). 2 These statements are generally accompanied by Summary of Findings (SoF) tables and evidence-todecision (EtD) frameworks to transparently summarize and present the evidence to formulate a recommendation. 2 Informal recommendations generally omit some or all the steps in the guideline development process. Hence, the methodology used to produce these statements is often not as rigorous or transparent as that used for formal recommendations. Nonetheless, informal recommendations need to be actionable 2 and can be used by clinicians, policymakers, and program managers to make clinical and public health decisions which is why they were included in our assessment of divergence. Strong recommendation against the intervention -1 Conditional/weak recommendation against the intervention 0 Conditional recommendation for either the "intervention or comparator" or recommendation "neither for nor against the intervention" +1 Conditional/weak recommendation for the intervention +2 Strong recommendation for the intervention J o u r n a l P r e -p r o o f Second, we reviewed actionable statements from guidelines that were not issued on the RecMap but were otherwise published from a key organization or contained topics that were comparable to statements issued on the RecMap. We used key organization websites and an archive of guidance literature organized for the RecMap to search for these documents. 1 We proceeded to sort comparable guidelines by reviewing their title and abstract. Guidelines with similar topics were reviewed together alongside existing actionable statements on the RecMap. Any possibly divergent statement was flagged and inputted on the same Excel sheet as statements flagged directly from the RecMap. Unknown impact on VOC however, preventing community transmission may decrease chance of its emergence. WHO concluded there is insufficient evidence to prove remdesivir has effects for patient important outcomes such as mortality, need for mechanical ventilation, and time to clinical improvement. WHO also considered additional resource and cost-constraints across countries. Therefore, they judged that the balance of effects favours the comparison group (standard care) • The Taskforce concluded small net benefits due to probable reduction of death, the safety profile of remdesivir, and probable reduction of serious adverse events for this population • ACOEM also compared desirable and undesirable effects to formulate a conditional recommendation for the intervention but also acknowledged opportunity-costs of intervention • Differences in the interpretation of the ACTT-1 and Solidarity study were observed between WHO and other guidelines. NIH primarily considered results from ACTT-1 study but also assessed results from Solidarity study Theme 2: Differences in the included studies/evidence • Taskforce used evidence from 3 trials, but the evidence was uncertain for death, need for invasive mechanical ventilation, rates of hospitalization. Two of these studies were also included by NIH • Taskforce included a pilot double-blind safety and feasibility study evaluating highdose intravenous zinc in hospitalized patients with COVID-19 that was excluded by NIH. Similarly, NIH included an observational and multi-cohort study on the effects of zinc on survival that was excluded by the Taskforce Theme 3: Differences in the interpretation of evidence and assessments of quality • Taskforce found low certainty of evidence (insufficient evidence) overall and issued a strong recommendation against its use unless in clinical trials • NIH made a conditional or moderate recommendation against its use unless it's for clinical trials because zinc has not shown to have clinical benefit and may be harmful when increasing doses. Existing trials had limitations in the studies Delaying the interval between the first and second dose for COVID-19 vaccines CDC ECDC PHAC Subgroup considerations of the intervention Theme 2: Differences in the included studies/evidence • PHAC considered evidence from vaccine studies after one dose • PHAC did not include any direct evidence to support delaying vaccines for 4months but provided rationale from their population modelling studies which predicted reduction in symptomatic infection, hospitalization, and death under certain circumstances • ECDC did not provide a direct statement or direct evidence concerning how long vaccine dosages should be delayed. They summarized evidence for dosing intervals and pre-print studies evaluating immunity after one dose. The study did not evaluate immunity beyond 21 days. • CDC did not recommend delaying the second dose for more than 6-weeks because of the limited available direct evidence on the effectiveness of the intervention. Theme 2: Differences in the included evidence/studies • WHO and the Taskforce used evidence from different systematic reviews to formulate their recommendations Theme 3: Differences in the interpretation of evidence and assessments of quality • WHO stated current studies on mother-to-child transmission varied in rigor, therefore limiting interpretation of these results. WHO issued a strong recommendation for not changing the mode of birth due to COVID-19 status in their guideline • The Taskforce stated desirable effects outweigh undesirable effects. However, the evidence was limited thus likely resulting in a conditional recommendation Rooming mothers with COVID-19 with their newborns after birth Australian Clinical Taskforce WHO Theme 3: Differences in the interpretation of evidence and assessments of quality • WHO stated mother-infant contact has many important benefits. They judged that several important benefits outweigh potential (and likely mild) harms of motherchild transmission • The Taskforce also favoured the intervention of rooming (not separating the mother and infant) due to substantial benefits. The certainty of evidence for mother-infant transmission was very low because they primarily relied on case reports and case series. Taskforce also stated there are substantial benefits which favours the intervention. The Taskforce issued a conditional recommendation overall Relaxing certain restrictions for vaccinated travellers/population CDC PHAC WHO Theme 3: Differences in the interpretation of evidence and assessments of quality • PHAC stated there is no current evidence to support lifting restrictions for vaccinated populations. Likewise, WHO stated critical unknowns of vaccine efficacy and effectiveness to reduce transmission, thus issued recommendations against reducing restrictions • Evidence from CDC's scientific brief suggested vaccinated groups are less likely to have asymptomatic infection and are potentially less likely to transmit the virus. • CDC made their statement considering studies on population attitudes and behaviours towards vaccination in addition to using data evaluating vaccine effectiveness. To increase uptake in the American population, they relaxed some restrictions for vaccinated individuals J o u r n a l P r e -p r o o f Getting trustworthy guidelines into the hands of decisionmakers and supporting their consideration of contextual factors for implementation globally: recommendation mapping of COVID-19 guidelines A guide to interpreting discordant systematic reviews Multiple systematic reviews: Methods for assessing discordances of results Strength of Recommendation and Quality of Evidence for Recommendations in Current Infectious Diseases Society of America Guidelines A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations GRADE: An emerging consensus on rating quality of evidence and strength of recommendations Visual transformation for guidelines presentation of the strength of recommendations and the certainty of evidence GRADE: Going from evidence to recommendations Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise Cleaning and Disinfection of environmental surfaces in the context of COVID-19 COVID-19: Cleaning and Disinfecting Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply Risk Assessment: SARS-CoV-2 -Increased Circulation of Variants of Concern and Vaccine Rollout in the EU/EAA, 14 th Update World Health Organization. Therapeutics and COVID-19: Living Guideline National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19 IDSA Guidelines on the Treatment and Management of Patients with COVID-19 COVID-19 rapid guideline: Managing COVID-19 V3.0 Coronavirus (COVID-19). Reed Grp COVID-19) Treatment Guidelines Surviving Sepsis Campaign Guidelines on the Management of Adults with Coronavirus Disease 2019 (COVID-19) in the ICU: First Update Public Health Agency of Canada. Clinical management of patients with COVID-19: Second interim guidance Interim Public Health Recommendations for Fully Vaccinated People Interim position paper: considerations regarding proof of COVID-19 vaccination for international travellers Adolopment -a new term added to the Clinical Epidemiology Lexicon Public Trust in Government and Compliance with Policy during COVID-19 Pandemic: Empirical Evidence from Vietnam. Public Organ Rev 2021 Living systematic reviews: 4. Living guideline recommendations Link: CRediT Author Statement Writing -Review & Editing Tamara Lotfi 1,2 : Methodology, Writing -Review & Editing, Project Administration Ashley Motillal, Lorenzo Moja Writing -Review & Editing Holger J. Schünemann 1,2,5 : Conceptualization, Methodology, Formal analysis, Investigation, Resources, Writing -Original Draft, Writing -Review & Editing, Visualization, Supervision J o u r n a l P r e -p r o o f